link to RWJMS home page
Banner Image Here

Clinical Research

Clinical Trials in Multiple Sclerosis

Beneficial effect of Dimethyl Fumarate (Tecfidera®) in MS may involve the development of regulatory macrophages/microglia.


Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated with Copaxone® (Immune Studies)


A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™


(Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)


Clinical trials in Epilepsy:

Randomized, Double-Blind, Placebo-Controlled Clinical Trial of SAGE-547 for the Treatment of Patients With Super-Refractory Status Epilepticus, Sage Pharmaceuticals 


Multicenter study of Eslicarbazepine acetate monotherapy in refractory epilepsy, Sunovion Pharmaceuticals


Multicenter study of Eslicarbazepine acetate polytherapy in refractory epilepsy, Sunovion Pharmaceuticals



Clinical Trials in Movement Disorder:

AbbVie:  A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).


AbbVie:  An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)


Biogen:  Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)


Biogen:  Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003


CHID:  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort


St.Jude:  Post Market Clinical Follow Up Evaluation the Infinity Deep Brain Stimulation Implantable Pulse Generator System


PENDING for Movement Disorder:

Sun Pharma Advanced Research Company Limited (SPARC)

-A phase 2, randomized, double-blind, placebo-controlled, study of K0706 in subjects with early Parkinson’s disease



Clinical Trials in Neuromuscular Diseases: 

International Guillain-Barré Syndrome Outcome Study (IGOS):

Guillain-Barré syndrome (GBS) is an acute inflammatory predominantly demyelinating polyneuropathy with a highly variable clinical course and outcome. The IGOS is a worldwide prospective study, conducted by the Inflammatory Neuropathy Consortium (INC) that aims to define biomarkers for disease activity and recovery and to develop prognostic models to predict the clinical course and outcome in individual patients with Guillain-Barré syndrome (GBS).


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (PATH, IgPro20)

CIDP is an acquired chronic immune-mediated predominantly demyelinating disorder of the peripheral nervous system (PNS), which is often treated with intravenous immunoglobulin (IVIG). This trial is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of patients with CIDP.


Oral Fingolimod (FTY720) For The Treatment Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP)


Characterization of Agrin/LRP4 antiobdy-positive myasthenia gravis.


Clinical Trials in Stroke:

NAVIGATE ESUS - Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg.


MISTIE 3 - A phase III, randomized, open-label, 500-subject clinical trial of

minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage.


POINT - Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial, a Randomized, Double-blind, Multicenter Clinical Trial.